ClinicalTrials.gg
TerminatedNCT01980875Updated Nov 19, 2018Results posted

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Idelalisib and Chlorambucil in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 18 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
16th of 25
57 · median 102
Started
2015
with 2 others
Phase 3
8 of 25
none open now
Registered
14th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 16th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 14th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (PFS) in participants with previously untreated chronic lymphocytic leukemia (CLL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Not a candidate for fludarabine therapy based on either:

    1. \< 70 mL/min, or
    2. Cumulative Illness Rating Scale score > 6, by assessment of the investigator
  • Diagnosis of B-cell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
  • No prior therapy for CLL other than for disease complications.
  • CLL that warrants treatment
  • Presence of measurable lymphadenopathy
  • (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

  • Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
  • Known presence of myelodysplastic syndrome
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
  • Ongoing liver injury
  • Ongoing drug-induced pneumonitis
  • Ongoing inflammatory bowel disease
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy other than corticosteroids
  • Concurrent participation in another therapeutic clinical trial
  • Undergone major surgery within 30 days prior to randomization
  • Known or intolerance to any of the active substances or in the formulations for idelalisib, obinutuzumab, or chlorambucil
  • History of non-infectious pneumonitis
  • Received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Safety Run-In: Idelalisib+obinutuzumab

    Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.

    Drug: Idelalisib · Drug: Obinutuzumab

  • Experimental
    Randomized: Idelalisib+obinutuzumab

    Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.

    Drug: Idelalisib · Drug: Obinutuzumab

  • Active comparator
    Randomized: Obinutuzumab+chlorambucil

    Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.

    Drug: Chlorambucil · Drug: Obinutuzumab

Interventions

  • 150 mg tablet administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

  • 2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses

  • 1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).

    Time frame: Up to 11 months

Secondary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.

    Time frame: Up to 11 months

  2. Nodal Response Rate

    Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

    Time frame: Up to 11 months

  3. Complete Response Rate

    Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

    Time frame: Up to 11 months

  4. Overall Survival

    Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.

    Time frame: Up to 11 months

  5. Minimal Residual Disease Negativity Rate at Week 36

    Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of obinutuzumab after the original scheduled date, the MRD assessment was performed no less than 12 weeks after the last dose of obinutuzumab. MRD negativity rate was to be assessed by an IRC.

    Time frame: Up to 11 months

07

Results

Posted Jun 28, 2017
Limitations and caveats
The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant.

Participant flow

Participants were enrolled at study sites in Australia, Europe, and North America. The first participant was screened on 21 April 2015. The last study visit occurred on 13 May 2016.

Participant flow — Overall Study
MilestoneSafety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+Chlorambucil
Started82524
Completed000
Not completed82524
Withdrew: Withdrew consent111
Withdrew: Study terminated by sponsor72422
Withdrew: Lost to follow-up001

Outcome measures

PrimaryProgression-Free Survival

Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).

Time frame:
Up to 11 months

No measurements were reported for this outcome.

SecondaryOverall Response Rate

Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.

Time frame:
Up to 11 months

No measurements were reported for this outcome.

SecondaryNodal Response Rate

Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

Time frame:
Up to 11 months

No measurements were reported for this outcome.

SecondaryComplete Response Rate

Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

Time frame:
Up to 11 months

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.

Time frame:
Up to 11 months

No measurements were reported for this outcome.

SecondaryMinimal Residual Disease Negativity Rate at Week 36

Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of obinutuzumab after the original scheduled date, the MRD assessment was performed no less than 12 weeks after the last dose of obinutuzumab. MRD negativity rate was to be assessed by an IRC.

Time frame:
Up to 11 months

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to the last dose date plus 30 days (maximum: 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-In: Idelalisib+Obinutuzumab0/8 (0%)2/8 (25%)8/8 (100%)
Randomized: Idelalisib+Obinutuzumab0/24 (0%)12/24 (50%)19/24 (79.2%)
Randomized: Obinutuzumab+Chlorambucil0/23 (0%)8/23 (34.8%)17/23 (73.9%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventSafety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+Chlorambucil
DiarrhoeaGastrointestinal disorders1/80/240/23
LeukoencephalopathyNervous system disorders1/80/240/23
AnaemiaBlood and lymphatic system disorders0/82/241/23
PneumonitisRespiratory, thoracic and mediastinal disorders0/82/240/23
Febrile neutropeniaBlood and lymphatic system disorders0/81/241/23
HypersensitivityImmune system disorders0/80/241/23
Secondary immunodeficiencyImmune system disorders0/80/241/23
GastroenteritisInfections and infestations0/80/241/23
Herpes zosterInfections and infestations0/80/241/23
PneumoniaInfections and infestations0/80/241/23
Most frequent other events
Showing 10 of 66
Most frequent other events
EventSafety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+Chlorambucil
Alanine aminotransferase increasedInvestigations7/85/241/23
Aspartate aminotransferase increasedInvestigations7/85/241/23
Infusion related reactionInjury, poisoning and procedural complications2/83/2414/23
NeutropeniaBlood and lymphatic system disorders4/86/249/23
DiarrhoeaGastrointestinal disorders4/84/241/23
ThrombocytopeniaBlood and lymphatic system disorders3/82/241/23
AnaemiaBlood and lymphatic system disorders2/86/242/23
ConstipationGastrointestinal disorders2/82/241/23
NauseaGastrointestinal disorders2/82/244/23
Influenza like illnessGeneral disorders2/80/240/23

Baseline characteristics

Intent-to-Treat Analysis Set: participants who were randomized regardless of whether participants received any study drug(s), or received a different regimen from the regimen to which they were randomized.

Age, Continuous
Age, Continuous(years)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Mean67.1 ± 8.1072.2 ± 8.2371.1 ± 6.8471.1 ± 7.70
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Female38920
Male5171537
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Black or African American1001
White7222150
Other0101
Not Permitted0235
Region of Enrollment
Region of Enrollment(participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Canada1102
Belgium0112
United States53412
Poland2141228
United Kingdom0123
France0325
Australia0134
Spain0101
Rai Stage
Rai Stage(Participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Stage I-II311923
Stage III-IV5141534
IgHV Mutation
IgHV Mutation(Participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Unmutated5161738
Mutated39719
17p Deletion in CLL Cells
17p Deletion in CLL Cells(Participants)Safety Run-In: Idelalisib+ObinutuzumabRandomized: Idelalisib+ObinutuzumabRandomized: Obinutuzumab+ChlorambucilTotal
Present0336
Absent8222151
08

Study locations

18 sites
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Santa Monica, California 90404, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Saint Francis Cancer Center
    Greenville, South Carolina 29607, United States
  • St Vincent Hospital, Sydney
    Darlinghurst, New South Wales 2010, Australia
  • UZ Ghent- hematology
    Ghent, 9000, Belgium
  • Royal Victoria Regional Health Centre - Simcoe Musk
    Barrie, Ontario L4M 6M2, Canada
  • Centre Hospitalier du Mans
    Le Mans, 72037, France
  • Centre Hospitalier de Perpignan
    Perpignan Cedex 9, 66046-BP 49954, France
  • Szpital Specjalistyczny w Brzozowie, Oddzial Hematologii Onkologicznej
    Brzozow, Podkarpackie 36-200, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • Wojewódzki Szpital Specjalistyczny w Legnicy
    Legnica, 59-220, Poland
  • Wojewodzki Szpital Specjalistyczny, im. M. Kopernika Klinika Hematologii Uniwersytetu Medycznego
    Lodz, 93-510, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
    Olsztyn, 10-228, Poland
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • East Kent Hospitals University NHS Foundation Trust
    Canterbury, Kent CT1 3NG, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in May 2016, 12 months.

Results were first posted in Jun 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 11, 2013
StartActual
Apr 21, 2015
Primary completionActual
May 13, 2016
CompletionActual
May 13, 2016
Results first posted
Jun 28, 2017
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01980875
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Apr 21, 2015
Primary completion
May 13, 2016
Completion
May 13, 2016
Results posted
Jun 28, 2017
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion